Fly News Breaks for February 11, 2020
Feb 11, 2020 | 08:31 EDT
SunTrust analyst Gregg Gilbert raised his price target on Allergan (AGN) to $202 and kept his Buy rating after its Q4 earnings beat, saying its "solid" revenue growth was driven by the higher sales across most therapeutic areas, including for its key products Botox Therapeutic, Botox Cosmetic, and Vraylar. Gilbert adds that Allegan could see more upside if the stock price of AbbVie (ABBV) continues to rise ahead of their merger closing expected at the end of Q1.
News For AGN;ABBV From the Last 2 Days